BioWorld Asia

Jan. 9, 2008

Addex, Merck Ink $702M Deal for Schizophrenia Compound

Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International) Read More

NicOx Renews Research Deal with Pfizer in Ophthalmology

Gene Variant Could Provide Clues to the Cause of ALS

Silence Tries to Calm Investors After Share Price Takes a Dive

EMA Promises to Boost Professionalism in 2008

Faust Signs Research Deal with Takeda for GPCRs

Sepracor Enters $175M Deal with Bial for Epilepsy Drug

Biotech Industry Welcomes EU Support for its Products

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Businesspeople shaking hands, meeting with cityscape, charts

Deals and an M&A strengthen end-of-year numbers

BioWorld

Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...

Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints

BioWorld

Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...